An Open-Label, Phase 2a/2b Study of KRT-232 in Subjects With
Primary Myelofibrosis (PMF), Post–Polycythemia Vera MF
(Post–PV-MF), Or Post–Essential Thrombocythemia MF (Post–
ET-MF) Who Have Failed Prior Treatment with a JAK Inhibitor
In this study, we will learn about a drug called KRT-232. KRT-232 will be called “the study drug”. This is the first study the study drug is used for participants with myelofibrosis (MF). This study will evaluate how well tolerated the study drug is when given to participants with MF, and whether the study drug can improve your MF. The study drug has been given to about 170 participants with different cancers and disorders (other than MF). Some of these studies are ongoing.
The study drug is a small molecule inhibitor and can reverse a mechanism through which unhealthy or tumor cells can survive and grow. This study will test if the study drug can restore the function of your healthy bone marrow cells and reduce the symptoms of your MF.
Eligible subjects must meet the following:
-Be at least 18 years or older,
-Have been diagnosed with myelofibrosis
-Your disease has a lack of response to previous ruxolitinib treatment, or your disease progressed any time during prior ruxolitinib treatment
18 - n/a
Healthy Volunteers Needed
Duration of Participation
If you participate in the study, the amount of time you will be on study treatment or be followed up for health information as part of the study depends on how you respond to the study treatment.
You will continue study drug treatment until your MF worsens or until you can no longer tolerate study drug treatment. If you stop study drug treatment, your investigator will continue to follow-up with you to see how well you are and discuss with you if treatment outside of this study is necessary. You will be contacted approximately every 12 weeks from your last dose of study drug.
Clinical Trials Information Line
Kartos Therapeutics, Inc.